NewAmsterdam Pharma Co N.V. (NAMS) Balance Sheet
As of 2026-06-30 (10-Q), NewAmsterdam Pharma Co N.V. (NAMS) reported total assets of $704.5M, total liabilities of $73.0M and shareholders' equity of $631.4M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $425.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAMSNewAmsterdam Pharma Co N.V.Follow NAMS — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 17 days
| Line | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|
| Cash and equivalents | 467.7 | 340.5 | 771.7 | 491.3 | 425.5 | |
| Short-term investments | — | — | 62.4 | 146.2 | 209.7 | |
| Current assets | 478.0 | 346.8 | 863.4 | 675.7 | 659.2 | |
| Total assets | 478.5 | 347.1 | 864.6 | 769.3 | 704.5 | |
| Current liabilities | 36.1 | 49.9 | 106.9 | 85.8 | 73.0 | |
| Total liabilities | 48.4 | 58.7 | 107.1 | 85.9 | 73.0 | |
| Shareholders' equity | 430.1 | 288.4 | 757.5 | 683.4 | 631.4 |
USD millions · SEC XBRL
NewAmsterdam Pharma Co N.V. — questions
- How much cash does NewAmsterdam Pharma Co N.V. have?
- $425.5M in cash and cash equivalents as of 2026-06-30.
- What are NewAmsterdam Pharma Co N.V.'s total assets?
- $704.5M as of 2026-06-30.
- What is NewAmsterdam Pharma Co N.V.'s shareholders' equity?
- $631.4M as of 2026-06-30.
Every figure on this page comes from NewAmsterdam Pharma Co N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.